Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.
|Audit||Compensation||Nominating and Governance||Strategy and Science|
|Henry E. Blair|
Chairman, Former President and Chief Executive Officer
Henry E. Blair has served as Chairman of the Dyax Board since the Company's merger with Protein Engineering Corporation in 1995. From 1989 to 2008, Mr. Blair served as President and Chief Executive Officer of Dyax Corp. and was a director and officer since co-founding the company in 1989. Mr. Blair has over thirty years of experience working in the biopharmaceutical industry. In addition to Dyax, he co-founded Genzyme Corporation. His enzyme replacement therapy research for Gaucher disease, while at Tufts University School of Medicine, was largely responsible for Genzyme's first therapeutic program and flagship product, Cerezyme®. He also co-founded Biocode, Inc., GelTex Pharmaceuticals, Inc., and Biotage, Inc., the predecessor to Dyax Corp. Additionally, Mr. Blair has previously served on several public companies' boards particularly during their start-up phases including GTC Biotherapeutics, Esperion Therapeutics, Inc., Celtrix Pharmaceuticals, Inc. and DynaGen, Inc. In addition to these directorships, Mr. Blair has served on the board of overseers at Tufts University School of Medicine and the Lahey Hitchcock Clinic and was a trustee of the Harvard-affiliated Center for Blood Research, Inc.
|Ron Cohen, M.D.|
President and Chief Executive Officer
Acorda Therapeutics, Inc.
Dr. Ron Cohen is the Founder, President and Chief Executive Officer of Acorda Therapeutics, a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and related nervous system disorders. Previously, he was a principal and officer at the startup Advanced Tissue Sciences, Inc. Dr. Cohen is Chairman of the Emerging Company Section of the Biotechnology Industry Organization (BIO) and a member of the Executive Committee of the Board of BIO. He previously served as Director and Chairman of the New York Biotechnology Association. He also serves as a member of the Columbia-Presbyterian Health Sciences Advisory Council. Dr. Cohen received his B.A. with honors in Psychology from Princeton University and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center and is Board Certified in Internal Medicine.
|James W. Fordyce|
MEDNA Partners LLC
James W. Fordyce has been a director of Dyax since 1995. Mr. Fordyce is currently Managing Partner of MEDNA Partners LLC, a private advisory firm. From 1981 to 2004, he was a general partner of Prince Ventures LP, a venture capital management firm focused on investments in medicine and the life sciences. From 1998 to 2004, Mr. Fordyce also served as the Managing Member of Fordyce & Gabrielson LLC, a private investment management firm. He is a member of the Board of Directors of several privately held companies an currently serves as Chairman of the Board of Directors of the Albert and Mary Lasker Foundation.
|Mary Ann Gray, Ph.D.|
Founder and President
Gray Strategic Advisors, LLC
Mary Ann Gray, Ph.D. has been a director of Dyax since February 2004. Dr. Gray established Gray Strategic Advisors, LLC in August, 2003 to provide strategic advice to both public and private biotechnology companies. From 1999 to July 2003, she served as a Senior Analyst and Portfolio Manager of the Federated Kaufmann Fund, focusing on both public and private healthcare investments. Prior to joining the Kaufmann Fund, Dr. Gray was a sell-side biotechnology analyst with Kidder Peabody, and held similar positions with Warburg Dillon Read from 1996 to 1998 and with Raymond James & Associates. Additionally, Dr. Gray has over twelve years of experience as a scientist in academia and industry. She held scientific positions at Schering Plough Corporation and NeoRx Corporation, and early in her career Dr. Gray managed pre-clinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute. She is also a director of Acadia Pharmaceuticals and Senomyx, Inc.
|Thomas L. Kempner|
Chairman and Chief Executive Officer
Loeb Partners Corporation
Thomas L. Kempner has been a director of Dyax since 1995, and previously was a director of Protein Engineering Corporation before its merger with Dyax. Mr. Kempner has been Chairman and Chief Executive Officer of Loeb Partners Corporation, an investment banking firm, and its predecessors since 1978. He is also President of Pinpoint Partners Corporation, the general partner of the Loeb Investment Partnerships. Mr. Kempner is a director of FuelCell Energy, IGENE BioTechnology, Inc., and Intersections, Inc. Mr. Kempner also serves as a director emeritus of Northwest Airlines, Inc.
|Marc D. Kozin|
Senior Advisor, L.E.K. Consulting
Marc D. Kozin joined the Dyax Corp. Board of Directors in October 2012. Mr. Kozin is currently a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm, and has nearly 30 years of domestic and international experience in advising biopharmaceutical, life sciences and medical technology companies. During his tenure at L.E.K., Mr. Kozin held positions of increasing responsibility that culminated in serving as the President of the North American practice from 1997-2012. Currently, Mr. Kozin sits on the board of directors at two additional publicly traded companies, Endocyte, Inc. (ECYT) and UFP Technologies (UFPT). He also serves on the Strategic Advisory Board of HealthCare Royalty Partners.
Mr. Kozin received his B.A., magna cum laude, in Economics from Duke University and an M.B.A. with distinction from The Wharton School of the University of Pennsylvania.
|David J. McLachlan|
Former Executive Vice President and Chief Financial Officer
David J. McLachlan has been a director of Dyax since 1999. He was the Executive Vice President and Chief Financial Officer of Genzyme Corporation from 1989 to 1999 and a senior advisor to Genzyme's chairman and chief executive officer through June 2004. Prior to joining Genzyme, Mr. McLachlan served as Chief Financial Officer and Vice President of Adams-Russell Company, an electronic component supplier and cable television operator. Mr. McLachlan currently serves on the Board of Directors of Skyworks Solutions, Inc., a manufacturer of analog, mixed signal and digital semiconductors for mobile communications.
Chief Executive Officer
Paolo Pucci is Chief Executive Officer and member of the Board of Directors of ArQule Inc., a clinical-stage biotechnology company that is researching and developing innovative cancer therapeutics targeting critical biological processes implicated in a wide range of cancers. Prior to ArQule, Mr. Pucci was at Bayer AG, where he held sequential responsibilities as Country Head Bayer Italy Pharmaceuticals, President & SVP Bayer Pharmaceuticals North America - Global Specialty Pharmaceuticals, and member of the Bayer Pharmaceuticals Executive Committee, concluding his tenure as president in charge of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Units. Prior to his tenure at Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci holds an MBA from the University of Chicago and is a graduate of the Universita Degli Studi Di Napoli in Naples, Italy.